Stage III nonsmall cell lung cancer (NSCLC) comprises about one-third of NSCLC patients
and is very heterogeneous with varying and mostly poor prognosis. It is also called “…

Introduction Afatinib is an effective first-line treatment in patients with epidermal growth factor
receptor (EGFR)-mutated non–small-cell lung cancer (NSCLC) and has shown activity in …

Purpose The advent of immune checkpoint inhibitors (ICIs) has revolutionized the treatment
of advanced NSCLC, leading to a string of approvals in recent years. Herein, a narrative …

The reason for weight loss at high altitudes is largely unknown. To date, studies have been
unable to differentiate between weight loss due to hypobaric hypoxia and that related to …

Immune microenvironment plays a critical role in lung cancer control versus progression
and metastasis. In this investigation, we explored the effect of tumor-infiltrating lymphocyte …

Objectives: Myeloid-derived suppressor cells (MDSCs) have been described as suppressors
of T-cell functions in many tumor models. However, MDSC in HIV-1 infection have not been …

Background Atypical EGFR mutations occur in 10%-30% of non-small-cell lung cancer (NSCLC)
patients with EGFR mutations and their sensitivity to classical epidermal growth factor …

Purpose In 2016, the University of Munich Molecular Tumor Board (MTB) was implemented
to initiate a precision oncology program. This review of cases was conducted to assess …

Background Concurrent chemotherapy and thoracic radiotherapy followed by prophylactic
cranial irradiation (PCI) is the standard treatment in limited-disease small-cell lung cancer (LD…

Introduction The NICOLAS study is the first completed single-arm phase II trial in stage III
NSCLC evaluating hierarchically first the safety and then the efficacy of adding nivolumab …